Therapy Areas: Inflammatory Diseases
US FDA Approves Pfizer's Biosimilar, Abrilada for Multiple Inflammatory Conditions
19 November 2019 - - The United States Food and Drug Administration has approved US-based pharmaceutical company Pfizer Inc.'s (NYSE: PFE) Abrilada (adalimumab-afzb), as a biosimilar to Humira&nb...
Novartis wins FDA approval of Adakveo to reduce frequency of pain crises in sickle cell disease patients
18 November 2019 - Healthcare company Novartis revealed on Friday the receipt of approval from the US Food and Drug Administration (FDA) for Adakveo to reduce the frequency of vaso-occlusive crises (V...
3SBio signs collaboration agreement with Verseau Therapeutics for VTX-0811
18 November 2019 - 3SBio Inc (HKEX:1530), a biotechnology company in China, has signed a collaboration agreement with United States-based Verseau Therapeutics Incorporated for VTX-0811, a monoclonal a...
PredictImmune Names Clark as Chief Technology Officer
15 November 2019 - - UK-based immune-mediated inflammatory disease specialist PredictImmune has named James Clark as chief technology officer, the company said.
Previously CEO of EnteroBiotix, s...
Finch Therapeutics Group expands Takeda Pharmaceutical collaboration
15 November 2019 - United States-based Finch Therapeutics Group Inc has expanded its collaboration with Japan-based Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK).It was reported yesterday ...
Magenta Therapeutics Presents First Immune Reset Results with Antibody-Drug Conjugate Across Multiple Autoimmune Diseases at ACR
13 November 2019 - - US-based biotechnology company Magenta Therapeutics (NASDAQ: MGTA) has presented new data showing successful immune reset with a single dose of its CD45-ADC in models of three aut...
Related Headlines

Data from Uncontrolled Gout Case Series Supports Immunomodulation with Krystexxa Strategy to Optimize Treatment Outcomes

Micreos announces grant of EUR2.5m for breakthrough skin problems under EU's Horizon 2020 funding

Axcella Health announces key milestones in development of AXA4010

Acadia Pharmaceuticals Names Subbiah as SVP and Global Head of Medical Affairs and Chief Medical Officer

KORU Medical Systems achieves higher USD0.02 per diluted share for Q3 2019

Active Biotech announces presentation of new preclinical data on naptumomab estafenatox at the Society for Immunotherapy of Cancer's 34th Annual Meeting

NovaBay Pharmaceuticals Launches Online Sales of CelleRx Skin Cleanser for Post-Aesthetic Dermatology and Cosmetic Surgery Procedures

Can-Fite Initiates Compassionate Use Programme for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients

Yas Holding Invests in Alvotech, Forges Partnership for Biosimilar Candidates

Vapogenix Touts Encouraging Phase II Results of Topical Non-Opioid Pain Medication

Navidea Biopharmaceuticals Touts Positive Results of First Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis

Terns Pharmaceuticals Receives Fast Track Designation from the FDA for TERN-101

Vapogenix announces positive Phase II results of topical non-opioid pain medication VPX638

Terns Pharmaceuticals awarded US FDA Fast Track Designation for TERN-101 to treat NASH

Active Biotech NeoTX announce dosing of the first patient in Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumours